Traws Pharma, Inc. (TRAW) Key Metrics
TRAW valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $5.7M
- Enterprise value
- $2.6M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 3.0
- Price / book
- 4.5
- EV / EBITDA
- 0.3
- Dividend yield
- —
- Beta
- 1.53
TRAW key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTRAW returns How much profit the business earns on the capital it uses.
Return on assets+281.1 pts
51.5%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin
−744.4%
2025 · hover or tap a bar for each year
20162025
Asset turnover+1,553.2%
0.16
2025 · hover or tap a bar for each year
20162025
TRAW financial health Debt, liquidity and how easily interest is covered.
Net debt+$17.5M
−$3.8M
2025 · hover or tap a bar for each year
20162025
Current ratio−66.9%
0.72
2025 · hover or tap a bar for each year
20162025
TRAW efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−1,076 days
364 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding−168,547 days
41,404 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle+167,471 days
-41,040 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue+92.7 pts
92.7%
2025 · hover or tap a bar for each year
20162025
TRAW valuation history
Fiscal year-endToday10-year median
TRAW returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TRAW debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TRAW cash returned to shareholders
DividendsBuybacksFree cash flow
TRAW price vs earnings per share
Share price at year-endEPS (right axis)
TRAW key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $9.5M | — | — | — | — | — | — | — | — | — |
| Enterprise value | $5.6M | — | — | — | — | — | — | — | — | — |
| P/E ratio | 1.0 | — | — | — | — | — | — | — | — | — |
| Price / sales | 3.4 | — | — | — | — | — | — | — | — | — |
| EV / sales | 2.0 | — | — | — | — | — | — | — | — | — |
| Earnings yield | 96.9% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −219.4% | — | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 25.4% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $1.13 | $8.88 | $18.64 | $16.14 | $63.75 | $174.68 | $143.62 | $791.25 | $8,437.50 | $12,768.75 |
| Per share | ||||||||||
| Revenue per share | $0.33 | — | — | — | — | — | — | — | — | — |
| Earnings per share | $1.09 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$2.17 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$2.48 | — | — | — | — | — | — | — | — | — |
| Cash per share | $0.46 | — | — | — | — | — | — | — | — | — |
| Book value per share | −$0.08 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | −$0.38 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.31 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 8.4M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | −97.2% | −51.0% | −61.8% | −283.5% | −253.6% | — | — | −274.9% |
| Return on assets (ROA) | 51.5% | −229.5% | −61.1% | −40.0% | −42.8% | −115.2% | −103.4% | −179.7% | −170.8% | −84.3% |
| Return on tangible assets | 113.3% | −219.0% | −83.5% | −48.2% | −29.1% | −125.9% | −90.8% | −114.8% | −483.9% | −84.7% |
| Free cash flow margin | −744.4% | — | — | — | — | — | −956.8% | — | — | −285.1% |
| Income quality (OCF / net income) | −1.98 | — | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Cash & short-term investments | $3.8M | $21.3M | $20.8M | $38.8M | $55.1M | $19.0M | $22.7M | $17.0M | $4.0M | $21.4M |
| Net debt | −$3.8M | −$21.3M | −$20.8M | −$38.8M | −$55.1M | −$19.0M | −$22.7M | −$17.0M | −$4.0M | −$21.4M |
| Current ratio | 0.72 | 2.16 | 2.46 | 4.89 | 9.06 | 1.97 | 2.83 | 2.11 | 0.49 | 2.27 |
| Quick ratio | 0.72 | 2.16 | 2.30 | 4.83 | 9.02 | 1.92 | 2.83 | 2.11 | 0.49 | 2.27 |
| Working capital | −$3.2M | $13.4M | $13.4M | $31.3M | $49.3M | $9.8M | $15.2M | $9.3M | −$5.1M | $12.9M |
| Invested capital | −$4.4M | −$53.0M | −$10.1M | −$10.4M | −$8.9M | −$12.8M | −$11.2M | −$11.6M | −$15.7M | −$17.2M |
| Tangible asset value | −$3.2M | −$31.6M | $10.7M | $28.3M | $46.1M | $6.2M | $11.6M | $5.4M | −$10.9M | $5.1M |
| Net current asset value | −$3.3M | −$31.6M | $10.6M | $28.3M | $46.1M | $6.0M | $11.4M | $5.2M | −$10.9M | $5.0M |
| Graham net-net per share | −$0.55 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | $2.4M | — | — | — | — | — | — | — | — | — |
| Capex / revenue | 92.7% | 0.0% | 6.2% | 0.0% | 0.0% | 6.5% | 2.5% | 0.0% | 0.0% | 0.0% |
| Capex / depreciation | 42.38 | 0.00 | 0.88 | 0.00 | 0.00 | 1.15 | 3.93 | 0.00 | 0.00 | 0.00 |
| Stock-based compensation / revenue | 26.1% | 615.0% | 575.7% | 518.6% | 254.9% | 159.7% | — | — | — | — |
| R&D / revenue | 435.2% | 57,659.7% | 5,057.5% | 5,046.9% | 3,228.8% | 7,315.2% | 711.7% | 1,373.7% | 2,418.2% | 361.9% |
| SG&A / revenue | 305.4% | 5,437.6% | 4,023.9% | 3,737.6% | 4,170.4% | 3,604.3% | 382.3% | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 363.6 | 1,439.8 | 38.0 | 46.0 | 52.5 | 106.7 | 11.1 | 14.0 | 20.9 | 50.5 |
| Days of inventory on hand | — | — | 22,139.5 | 10,663.2 | 10,937.0 | — | — | — | — | — |
| Days payables outstanding | 41,403.6 | 209,951.0 | 108,119.8 | 86,257.3 | 98,941.1 | — | — | — | — | — |
| Cash conversion cycle (days) | -41,039.9 | -208,511.2 | -85,942.4 | -75,548.1 | -87,951.6 | — | — | — | — | — |
| Receivables turnover | 1.00 | 0.25 | 9.62 | 7.93 | 6.95 | 3.42 | 32.83 | 26.13 | 17.49 | 7.23 |
| Payables turnover | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | — | — | 0.02 | 0.03 | 0.03 | 0.00 | — | — | — | — |
| Asset turnover | 0.16 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.10 | 0.11 | 0.06 | 0.24 |
| Average receivables | $2.8M | $891,500 | $23,500 | $28,500 | $32,500 | $67,500 | $66,500 | $47,000 | $45,000 | $767,500 |
| Average payables | $6.9M | $6.9M | $4.7M | $3.3M | $3.8M | $4.6M | $4.2M | $5.1M | $5.8M | $4.4M |
| Average inventory | — | — | $970,500 | $409,000 | $419,500 | $542,000 | — | — | — | — |
| Intangibles / total assets | 23.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from TRAW's annual financial statements (latest annual report filed April 15, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TRAW valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Traws Pharma traded at 1.0 times earnings. It returned $2.4 million to shareholders: $0 in dividends and $2.4 million in share buybacks.
See the TRAW income statement, the TRAW chart for price history, or the TRAW stock overview for the latest quote and news.
TRAW key metrics FAQ
What is Traws Pharma's P/E ratio?
Traws Pharma traded at 1.0 times earnings at the end of fiscal 2025.
Does Traws Pharma buy back its shares?
Yes. Traws Pharma spent $2.4 million on net share repurchases in fiscal 2025.
What is Traws Pharma's free cash flow yield?
Traws Pharma generated -$20.8 million of free cash flow in fiscal 2025, a free cash flow yield of −219.4% on its market value at year-end ($9.5 million).
What is Traws Pharma's current ratio?
Traws Pharma's current ratio was 0.72 at the end of fiscal 2025: current assets were 0.72 times current liabilities.